A Multidisciplinary Therapeutic Framework for Neuropsychiatric, Neurological and Functional Disorders, Encompassing Psychedelic, Pharmaceutical, Botanical and Nutraceutical Interventions, Delivery Systems and Lifestyle Modifications

Background: A person with depression, unresolved trauma, a substance problem, and cognitive complaints is treated differently depending on which practitioner they consult. A psychiatrist draws on the monoaminergic and glutamatergic literature. A licensed facilitator draws on the session literature. A naturopath draws on the botanical and nutritional literature. Each draws on a defensible evidence base, and none of the three literatures routinely cites the other two. No single reference covers the agents acting on these conditions across the disciplines that use them, with the evidentiary standing of each claim visible and the boundary of each practitioner’s authority stated.

Objective: To organize that agent population by mechanism of action rather than by regulatory status or professional tradition, assign an explicit evidence tier to every claim, characterize the route and bioavailability for every agent, and derive an operational logic for safety gating, interaction adjudication, and protocol construction that practitioners from differing disciplines and with varying prescribing authority can apply within their own scope.

Methods: A structured review was conducted with framework development, defining fifteen mechanism classes based on receptor pharmacology and downstream signalling. Each agent was characterized by its mechanism, dose range, route, established bioavailability, onset, duration, evidence tier, contraindications, and potential interactions. The evidence was evaluated through an international literature review and categorized into a single standardized tier system, regardless of jurisdiction: T1 for randomized controlled trials, T2 for controlled studies with limitations, T3 for observational or open-label studies, T4 for mechanistic evidence only, and T5 for traditional use.

Results: Fifteen classes are outlined across 154 subsections, covering areas like glutamatergic modulation, serotonergic psychedelics, entactogens, non-5-HT2A psychoactives, monoaminergic and inhibitory modulation, neurotrophic and neuroimmune agents, adaptogenic and mitochondrial support, pharmacokinetic modification, potentiation, cholinergic modulation, and circadian phase. Seventy-six agents are individually characterized. A condition matrix links them to sixty-eight indications, including cluster headache, tic disorders, traumatic brain injury, chronic pain, burnout, and insomnia, which are often missing from reviews despite substantial supporting data. The safety measures include six safety gates, eighteen interaction rules with specified severity, a seven-step construction process, and a role-scope matrix. Route and bioavailability are detailed for each agent: five deliver about the administered dose; several widely used agents reach systemic circulation at one to ten percent; and four are pharmacologically inert via their primary route.

Conclusions: A mechanism-first organization enables the evaluation of agents with varying evidentiary credibility and regulatory statuses within a single framework, without undervaluing weaker evidence or overestimating stronger cases. Three key points follow. The evidence tier pertains to the agent-indication-dose triplet, not the agent itself: for example, piracetam shows T1 evidence for myoclonus at 24 g daily and T4 for cognition at any dose. An additional axis, circadian phase, runs alongside dose, mechanism, and route; a shifted rhythm indicates deficiency and calls for the opposite intervention. When absorption or first-pass metabolism limits a compound rather than receptor pharmacology, the issue is a formulation problem and should be labelled as such. This framework is designed for complementary and adjunctive practices, highlights sections needing prescribing authority, and does not replace personalized clinical judgment.